Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Maria Letizia Cataldo"'
Autor:
Maria Letizia Cataldo, Pietro De Placido, Daniela Esposito, Luigi Formisano, Grazia Arpino, Mario Giuliano, Roberto Bianco, Carmine De Angelis, Bianca Maria Veneziani
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundHER2 is amplified or overexpressed in around 20% of breast cancers (BC). HER2-targeted therapies have significantly improved the prognosis of patients with HER2+ BC, however, de novo and acquired resistance to anti-HER2 treatment is common.
Externí odkaz:
https://doaj.org/article/c47abc091f734602ac1e42323130400f
Autor:
Raksha Bhat, Hariprasad Thangavel, Noor Mazin Abdulkareem, Suhas Vasaikar, Carmine De Angelis, Leon Bae, Maria Letizia Cataldo, Sarmistha Nanda, Xiaoyong Fu, Bing Zhang, Rachel Schiff, Meghana V. Trivedi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract G Protein-Coupled Receptors (GPCRs) represent the largest superfamily of cell-surface proteins. However, the expression and function of majority of GPCRs remain unexplored in breast cancer (BC). We interrogated the expression and phosphoryla
Externí odkaz:
https://doaj.org/article/f573b7bda516414bb4b2dfb6151cfce9
Autor:
Rachel Schiff, C. Kent Osborne, Rinath Jeselsohn, Valerie M. Jansen, Mothaffar F. Rimawi, Dennis J. Slamon, Sara A. Hurvitz, Ben H. Park, Jorge S. Reis-Filho, Britta Weigelt, David N. Brown, Pier Selenica, Joshua Donaldson, Jiangang Liu, Lacey M. Litchfield, Luca Malorni, Cristina Guarducci, Ilenia Migliaccio, Matteo Benelli, Susan G. Hilsenbeck, Tao Wang, Vidyalakshmi Sethunath, Lanfang Qin, Sarmistha Nanda, Jamunarani Veeraraghavan, Resel Pereira, Agostina Nardone, Maria Letizia Cataldo, Xiaoyong Fu, Carmine De Angelis
Supplementary Figure S1. ER, PR, and HER2 mRNA and protein levels across endocrine-sensitive (parental) and endocrine-resistant BC cell lines. Supplementary Figure S2. Reduced sensitivity to CDK4/6 inhibition is associated with IFN-signaling in ER+ a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca189794e5917e4f6ef6e2b541b4485
https://doi.org/10.1158/1078-0432.22481033.v1
https://doi.org/10.1158/1078-0432.22481033.v1
Autor:
Rachel Schiff, Mothaffar F. Rimawi, Charles Kent Osborne, Carolina Gutierrez, Aleix Prat, Jorge S. Reis-Filho, Britta Weigelt, Antonio C. Wolff, Anne Pavlick, Maria Letizia Cataldo, Meghana V. Trivedi, Susan G. Hilsenbeck, Sufeng Mao, Anna Tsimelzon, Tao Wang, Paolo Nuciforo, Vidyalakshmi Sethunath, Jamunarani Veeraraghavan, Yi Zheng, Chichung Wang, Kristin Roman, Linying Liu, Cliff C. Hoyt, Chandandeep Nagi, Carmine De Angelis
Purpose:Tumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2+ breast cancer. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::031b5b9794b637e6c789dcde83d54b35
https://doi.org/10.1158/1078-0432.c.6528806
https://doi.org/10.1158/1078-0432.c.6528806
Autor:
Rachel Schiff, Mothaffar F. Rimawi, Charles Kent Osborne, Carolina Gutierrez, Aleix Prat, Jorge S. Reis-Filho, Britta Weigelt, Antonio C. Wolff, Anne Pavlick, Maria Letizia Cataldo, Meghana V. Trivedi, Susan G. Hilsenbeck, Sufeng Mao, Anna Tsimelzon, Tao Wang, Paolo Nuciforo, Vidyalakshmi Sethunath, Jamunarani Veeraraghavan, Yi Zheng, Chichung Wang, Kristin Roman, Linying Liu, Cliff C. Hoyt, Chandandeep Nagi, Carmine De Angelis
Supplementary tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::108433fa384db8bcf8b43accd4a84765
https://doi.org/10.1158/1078-0432.22474505.v1
https://doi.org/10.1158/1078-0432.22474505.v1
Autor:
Rachel Schiff, C. Kent Osborne, Rinath Jeselsohn, Valerie M. Jansen, Mothaffar F. Rimawi, Dennis J. Slamon, Sara A. Hurvitz, Ben H. Park, Jorge S. Reis-Filho, Britta Weigelt, David N. Brown, Pier Selenica, Joshua Donaldson, Jiangang Liu, Lacey M. Litchfield, Luca Malorni, Cristina Guarducci, Ilenia Migliaccio, Matteo Benelli, Susan G. Hilsenbeck, Tao Wang, Vidyalakshmi Sethunath, Lanfang Qin, Sarmistha Nanda, Jamunarani Veeraraghavan, Resel Pereira, Agostina Nardone, Maria Letizia Cataldo, Xiaoyong Fu, Carmine De Angelis
Supplementary Table S1. Details of antibodies used in this study. Supplementary Table S2. Q-PCR primers. Supplementary Table S3. HALLMARK gene-set enrichment analysis (GSEA) of baseline tumor samples from the NeoPalANA trial. Supplementary Table S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54fbc573ea08835b98626276b9bebcac
https://doi.org/10.1158/1078-0432.22481027.v1
https://doi.org/10.1158/1078-0432.22481027.v1
Autor:
Rachel Schiff, C. Kent Osborne, Rinath Jeselsohn, Valerie M. Jansen, Mothaffar F. Rimawi, Dennis J. Slamon, Sara A. Hurvitz, Ben H. Park, Jorge S. Reis-Filho, Britta Weigelt, David N. Brown, Pier Selenica, Joshua Donaldson, Jiangang Liu, Lacey M. Litchfield, Luca Malorni, Cristina Guarducci, Ilenia Migliaccio, Matteo Benelli, Susan G. Hilsenbeck, Tao Wang, Vidyalakshmi Sethunath, Lanfang Qin, Sarmistha Nanda, Jamunarani Veeraraghavan, Resel Pereira, Agostina Nardone, Maria Letizia Cataldo, Xiaoyong Fu, Carmine De Angelis
Supplemental Materials and Methods and Materials present a complete description of methods, reagents, and statistics required to reproduce the experiments in the paper.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7459b34c8c31a9f7dcd0d4a39ecdab35
https://doi.org/10.1158/1078-0432.22481030
https://doi.org/10.1158/1078-0432.22481030
Autor:
Rachel Schiff, C. Kent Osborne, Rinath Jeselsohn, Valerie M. Jansen, Mothaffar F. Rimawi, Dennis J. Slamon, Sara A. Hurvitz, Ben H. Park, Jorge S. Reis-Filho, Britta Weigelt, David N. Brown, Pier Selenica, Joshua Donaldson, Jiangang Liu, Lacey M. Litchfield, Luca Malorni, Cristina Guarducci, Ilenia Migliaccio, Matteo Benelli, Susan G. Hilsenbeck, Tao Wang, Vidyalakshmi Sethunath, Lanfang Qin, Sarmistha Nanda, Jamunarani Veeraraghavan, Resel Pereira, Agostina Nardone, Maria Letizia Cataldo, Xiaoyong Fu, Carmine De Angelis
Purpose:Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor–positive (ER+)/HER2− breast cancer; however, intrinsic and acquired resistance is common. Elucidating the molecular features of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8bb0d5708665d69be9b5d18c151fab
https://doi.org/10.1158/1078-0432.c.6530603
https://doi.org/10.1158/1078-0432.c.6530603
Autor:
Britta Weigelt, Resel Pereira, C. Kent Osborne, Rinath Jeselsohn, Jiangang Liu, Vidyalakshmi Sethunath, Jamunarani Veeraraghavan, Rachel Schiff, Lanfang Qin, Luca Malorni, Pier Selenica, Carmine De Angelis, Xiaoyong Fu, Ilenia Migliaccio, David N Brown, Susan G. Hilsenbeck, Sarmistha Nanda, Joshua Donaldson, Valerie M. Jansen, Sara A. Hurvitz, Agostina Nardone, Dennis J. Slamon, Ben Ho Park, Tao Wang, Jorge S. Reis-Filho, Lacey M. Litchfield, C. Guarducci, Matteo Benelli, Maria Letizia Cataldo, Mothaffar F. Rimawi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 17
Purpose: Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor–positive (ER+)/HER2− breast cancer; however, intrinsic and acquired resistance is common. Elucidating the molecular features of
Autor:
Anna Tsimelzon, Meghana V. Trivedi, Britta Weigelt, Jamunarani Veeraraghavan, Carmine De Angelis, Chandandeep Nagi, Sufeng Mao, Carolina Gutierrez, Cliff Hoyt, Linying Liu, CK Osborne, Antonio C. Wolff, Chichung Wang, Yi Zheng, Anne Pavlick, Tao Wang, Susan G. Hilsenbeck, Kristin Roman, Aleix Prat, Vidyalakshmi Sethunath, Rachel Schiff, Jorge S. Reis-Filho, Paolo Nuciforo, Maria Letizia Cataldo, Mothaffar F. Rimawi
Publikováno v:
Clinical Cancer Research. 26:738-745
Purpose: Tumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2+ breast cancer. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemot